Obesity and metabolic syndrome in a psychiatric rehabilitation service

Australian and New Zealand Journal of Psychiatry

Volumn 41, Issue 7, 2007, Pages 606-610

  Tirupati, Srinivasan ^a   Chua, Ling Ern ^a  

^a James Fletcher Hospital   (Australia)

Author keywords

Metabolic syndrome X; Obesity; Psychotic disorders; Rehabilitation

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; OBESITY; PREVALENCE; PSYCHOSIS; REHABILITATION CARE; REHABILITATION CENTER; RISK REDUCTION;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY MASS INDEX; CHRONIC DISEASE; COMMUNITY MENTAL HEALTH SERVICES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; LITHIUM COMPOUNDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; REHABILITATION CENTERS; SCHIZOPHRENIA;

EID: 34250626447     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670701392841     Document Type: Article

References (30)

1. Newman, SC and Bland, RC. (1991) Mortality in a cohort of patients with schizophrenia: A record linkage study. Can J Psychiatry, 36, pp. 239-245.
2. Marder, SR, Essock, SM and Miller, AL (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 16, pp. 1334-1349.
3. Lambert, TJR and Chapman, LH. (2004) Diabetes, psychotic disorders and antipsychotic therapy: A consensus statement. Med J Aust, 181, pp. 544-548.
4. Green, A., Patel, J. and Goisman, R. (2000) Weight gain from novel antipsychotic drugs: Need for action. Gen Hosp Psychiatry, 22, pp. 224-235.
5. McElroy, SL, Frye, MA and Suppes, T. (2002) Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry, 63, pp. 207-213.
6. Wirshing, DA. (2004) Schizophrenia and obesity: Impact of antipsychotic medications. Acta Psychiatr Scand, 65, pp. 13-26.
7. Lakka, HM, Laaksonen, DE and Lakka, TA (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288, pp. 2709-2716.
8. McEvoy, JP, Meyer, JM and Goff, DC (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res, 80, pp. 19-32.
9. Fagiolini, A., Frank, E., Scott, JA, Turkin, S. and Kupfer, DJ. (2005) Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord, 7, pp. 424-430.
10. De Hert, M., van Winkel, R. and Van Eyck, D. (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res, 83, pp. 87-93.
11. McIntyre, RS, Konarski, JZ, Wilkins, K., Soczynska, JK and Kennedy, SH. (2006) Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry, 51, pp. 274-280.
12. Straker, D., Correll, CU and Kramer-Ginsberg, E. (2005) Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry, 162, pp. 1217-1221.
13. Fevre, PD. Le (2001) Improving the physical health of patients with schizophrenia: Therapeutic nihilism or realism?. Scott Med J, 46, pp. 11-31.
14. Ells, LJ, Lang, R. and Shields, JP (2006) Obesity and disability: A short review. Obes Rev, 7, pp. 341-345.
15. Allison, DB, Mackell, JA and McDonnell, DD. (2003) The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv, 54, pp. 565-567.
16. Von Korff, M., Wayne, K. and Lin, E. (2005) Potentially modifiable factors associated with disability among people with diabetes. Psychosom Med, 67, pp. 233-240.
17. Ali, S., Stone, MA, Peters, JL, Davies, MJ and Khunti, K. (2006) The prevalence of co-morbid depression in adults with Type 2 diabetes: A systematic review and meta-analysis. Diabet Med, 23, pp. 1165-1173.
18. Simon, GE, von Korff, M. and Saunders, K. (2006) Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry, 63, pp. 824-830.
19. Todaro, JF, Shen, BJ, Niaura, R. and Tilkemeier, PL. (2005) Prevalence of depressive disorders in men and women enrolled in cardiac rehabilitation. J Cardiopulm Rehabil, 25, pp. 78-79.
20. (2004) Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, pp. 596-601.
21. (2005) International Diabetes Federation, International Diabetes Federation, Brussels
22. Cameron, AJ, Wellborn, TA and Zimmet, PZ (2003) Overweight and obesity in Australia: The 1999-2000 Australian Diabetes, Obesity and Lifestyle study (AusDiab). Med J Aust, 178, pp. 427-432.
23. Zimmet, PZ, George, K., Alberti, MM and Shaw, JE. (2005) Mainstreaming the metabolic syndrome: A definitive definition. Med J Aust, 183, pp. 175-176.
24. Lamberti, JS, Olson, D. and Crilly, JF (2006) Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry, 163, pp. 1273-1276.
25. Allison, DB and Casey, DE. (2001) Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry, 62, pp. 22-31.
26. Correll, CU, Frederickson, AM., Kane, JM and Manu, P. (2007) Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res, 89, pp. 91-100.
27. Hu, FB, Manson, JE and Stampfer, MJ (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med, 345, pp. 790-797.
28. Nasrallah, HA, Meyer, JM and Goff, DC (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res, 86, pp. 15-22.
29. Newcomer, JW. (2004) Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry, 65, pp. 36-46.
30. Paton, C., Esop, R., Young, C. and Taylor, D. (2004) Obesity, dyslipidemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand, 110, pp. 299-305.